EGFR and head and neck squamous cell carcinoma: EGFR-targeting mAbs are approved for various oncologic indications and all share similar binding epitopes in the EGFR ECDIII as follows: cetuximab (mouse/human chimeric mAb approved for metastatic CRC and head and neck squamous cell carcinoma (HNSCC)), panitumumab (human mAb approved for metastatic CRC), and necitumumab (human mAb approved for NSCLC).